Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "Supplements"

101 News Found

Hester planning capacity expansion for Goat Pox vaccine
News | September 27, 2022

Hester planning capacity expansion for Goat Pox vaccine

Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine


Madhavbaug plans to foray in UAE, Europe & US
Healthcare | September 24, 2022

Madhavbaug plans to foray in UAE, Europe & US

To set up 50 lifestyle modification centres across the UAE in the next 24 months


Reasons for the surge in M& A in healthcare and pharmaceutical sectors in India: Ankit Poddar & Navroz Mahudawala, Candle Partners
Opinion | September 22, 2022

Reasons for the surge in M& A in healthcare and pharmaceutical sectors in India: Ankit Poddar & Navroz Mahudawala, Candle Partners

Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.


How nutrigenomics can help you plan an effective and healthy diet
Opinion | September 20, 2022

How nutrigenomics can help you plan an effective and healthy diet

Nutrigenomics is the study of how genes and diet (nutrients) interact. Gene variants (genetic differences) predict how an individual’s body will respond to certain nutrients.


Panacea Biotec received US FDA communication for Baddi facility
Drug Approval | September 09, 2022

Panacea Biotec received US FDA communication for Baddi facility

The OAI classification implies that the USFDA expects further corrective actions and may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved


Glenmark receives OAI from USFDA for Goa facility
News | August 28, 2022

Glenmark receives OAI from USFDA for Goa facility

Glenmark continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest.


Glenmark  receives OAI communication from US FDA
Drug Approval | August 24, 2022

Glenmark receives OAI communication from US FDA

The company continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest


Sun Pharma gets OAI from USFDA for Halol facility
Drug Approval | August 18, 2022

Sun Pharma gets OAI from USFDA for Halol facility

The OAI classification implies that the US FDA may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved


Thermo Fisher to expand dry powder media manufacturing facility in New York
News | August 05, 2022

Thermo Fisher to expand dry powder media manufacturing facility in New York

With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies


Cadila launches generic sitagliptin versions to treat uncontrolled type 2 diabetes
News | August 02, 2022

Cadila launches generic sitagliptin versions to treat uncontrolled type 2 diabetes

The two generic drugs have been launched under the brand names Jankey & Sitenali.